TABLE 2.

Performance of Agile 3+ versus FIB-4 and LSM by VCTE in identifying advanced fibrosis

	FIB-4	LSM	Agile 3+
AUROC (95% CI)	0.77 (0.73; 0.81)	0.83 (0.79; 0.86)	0.85 (0.81; 0.88)
Delong test p (vs. Agile 3+)	<0.0001	0.142	NA
Rule out cutoff	<1.3 (<65 y)	<8.0	<0.451
	<2.0 (≥65 y)	—	—
Percentage of patients	45	24	34
Se	0.77 (0.718; 0.822)	0.91 (0.875; 0.945)	0.91 (0.875; 0.945)
Sp	0.64 (0.695; 0.858)	0.37 (0.315; 0.425)	0.56 (0.503; 0.617)
NPV	0.76 (0.707; 0.813)	0.83 (0.766; 0.894)	0.88 (0.834; 0.926)
LR−	0.36	0.23	0.16
Gray zone
Percentage of patients (p-value vs. Agile 3+)	31 (p<0.001)	13 (p<0.001)	14
Rule in cutoff	≥2.67	>9.6	≥0.679
Percentage of patients	24	63	52
Se	0.38 (0.320; 0.440)	0.86 (0.817; 0.903)	0.80 (0.751; 0.849)
Sp	0.87 (0.831; 0.909)	0.58 (0.523; 0.637)	0.72 (0.669; 0.771)
PPV	0.72 (0.644; 0.796)	0.64 (0.589; 0.691)	0.71 (0.657; 0.763)
LR+	2.93	2.04	2.86

Advanced fibrosis defined as ≥F3.

Abbreviations: AUROC, area under the receiver operator curve; F3, fibrosis stage 3; FIB-4, fibrosis-4 index; LR+, positive likelihood ratio; LR−, negative likelihood ratio; LSM, liver stiffness measurement; NPV, negative predictive value; PPV, positive predictive value; Se, sensitivity; Sp, specificity; VCTE, vibration-controlled transient elastography.